VINH PHUC PHARMACEUTICAL JOINT - STOCK COMPANY

Belkins
With motto "for public health"​, the medical ethics of the physician in who produce as well as in business to defend the interest people the client Everlasting Lucky materia medica joint stock company (have VINPHACO business name) always exaltted is motto what VINPHACO always tend.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

CELL AND GENE THERAPY

INDYGENEUS AI SECURES PATHOGEN SEQUENCING FOR COVID-19 GENOMIC SURVEILLANCE INITIATIVES

IndyGeneUS AI | May 20, 2021

news image

Through collaborations, IndyGeneUS AI has acquired genomic analysis and testing capabilities. This pathogen sequencing capacity has emerged at a critical moment in efforts to improve genomic surveillance and monitor COVID-19 variant strains across the continent. IndyGeneUS founder and CEO Yusuf Henriques emphasized the importance of this work. "COVID-19 and its variants pose a danger to the entire African continent, so we must act quickly. Our partners understand the urgency ...

Read More

MEDICAL

AVANTGEN ANNOUNCES LICENSING OF ITS ANTI-SARS-COV-2 ANTIBODY CLONES TO IGM BIOSCIENCES FOR COVID-19 THERAPY DEVELOPMENT

AvantGen | January 12, 2021

news image

AvantGen, Inc., a San Diego-based biotechnology organization with a variety of innovation stages for neutralizer revelation and enhancement, and novel NK and T cell engager age, today reported permitting of a board of its anti-SARS-CoV-2 antibody clones to IGM Biosciences for COVID-19 therapy development. Utilizing its novel yeast show framework and huge different human antibody response libraries, AvantGen has distinguished a board of high partiality human monoclonal antibody clo...

Read More

CELL AND GENE THERAPY

SPECIFIC BIOLOGICS INC. ANNOUNCES THERAPEUTIC DEVELOPMENT AWARD FROM THE CYSTIC FIBROSIS FOUNDATION

Specific Biologics Inc. | December 08, 2021

news image

Specific Biologics Inc. an early-stage biotechnology company developing novel gene editing technologies, announced that it will receive more than US$527,000 to support the preclinical development of its Dualase™ gene editing platform to target a set of cystic fibrosis -causing nonsense mutations where patients currently have fewer therapeutic options available. "Incredible advancements in the treatment of cystic fibrosis have been made since the id...

Read More

RESEARCH

ABVERIS ANNOUNCES MULTI-TARGET, MULTI-YEAR THERAPEUTIC ANTIBODY DISCOVERY COLLABORATION WITH PROMETHEUS BIOSCIENCES

Abveris, Biosciences | November 12, 2021

news image

Abveris, a leader in antibody drug discovery announced that Prometheus Biosciences and Abveris have entered a multi-year collaboration to develop therapeutic antibodies against multiple targets. The partnership will expand Abveris's role in supporting the rapid development of the Prometheus Biosciences portfolio. The results of the collaboration will bring promising new therapeutics to patients suffering from a variety of immune-mediated diseases. Under this partnership agreem...

Read More
news image

CELL AND GENE THERAPY

INDYGENEUS AI SECURES PATHOGEN SEQUENCING FOR COVID-19 GENOMIC SURVEILLANCE INITIATIVES

IndyGeneUS AI | May 20, 2021

Through collaborations, IndyGeneUS AI has acquired genomic analysis and testing capabilities. This pathogen sequencing capacity has emerged at a critical moment in efforts to improve genomic surveillance and monitor COVID-19 variant strains across the continent. IndyGeneUS founder and CEO Yusuf Henriques emphasized the importance of this work. "COVID-19 and its variants pose a danger to the entire African continent, so we must act quickly. Our partners understand the urgency ...

Read More
news image

MEDICAL

AVANTGEN ANNOUNCES LICENSING OF ITS ANTI-SARS-COV-2 ANTIBODY CLONES TO IGM BIOSCIENCES FOR COVID-19 THERAPY DEVELOPMENT

AvantGen | January 12, 2021

AvantGen, Inc., a San Diego-based biotechnology organization with a variety of innovation stages for neutralizer revelation and enhancement, and novel NK and T cell engager age, today reported permitting of a board of its anti-SARS-CoV-2 antibody clones to IGM Biosciences for COVID-19 therapy development. Utilizing its novel yeast show framework and huge different human antibody response libraries, AvantGen has distinguished a board of high partiality human monoclonal antibody clo...

Read More
news image

CELL AND GENE THERAPY

SPECIFIC BIOLOGICS INC. ANNOUNCES THERAPEUTIC DEVELOPMENT AWARD FROM THE CYSTIC FIBROSIS FOUNDATION

Specific Biologics Inc. | December 08, 2021

Specific Biologics Inc. an early-stage biotechnology company developing novel gene editing technologies, announced that it will receive more than US$527,000 to support the preclinical development of its Dualase™ gene editing platform to target a set of cystic fibrosis -causing nonsense mutations where patients currently have fewer therapeutic options available. "Incredible advancements in the treatment of cystic fibrosis have been made since the id...

Read More
news image

RESEARCH

ABVERIS ANNOUNCES MULTI-TARGET, MULTI-YEAR THERAPEUTIC ANTIBODY DISCOVERY COLLABORATION WITH PROMETHEUS BIOSCIENCES

Abveris, Biosciences | November 12, 2021

Abveris, a leader in antibody drug discovery announced that Prometheus Biosciences and Abveris have entered a multi-year collaboration to develop therapeutic antibodies against multiple targets. The partnership will expand Abveris's role in supporting the rapid development of the Prometheus Biosciences portfolio. The results of the collaboration will bring promising new therapeutics to patients suffering from a variety of immune-mediated diseases. Under this partnership agreem...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us